Medacta Group SA
SIX:MOVE

Watchlist Manager
Medacta Group SA Logo
Medacta Group SA
SIX:MOVE
Watchlist
Price: 106.8 CHF 0.38%
Market Cap: 2.1B CHF
Have any thoughts about
Medacta Group SA?
Write Note

Medacta Group SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medacta Group SA
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Medacta Group SA
SIX:MOVE
Accrued Liabilities
€52.7m
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Metall Zug AG
SIX:METN
Accrued Liabilities
CHf24.2m
CAGR 3-Years
-27%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Sonova Holding AG
SIX:SOON
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Straumann Holding AG
SIX:STMN
Accrued Liabilities
CHf40m
CAGR 3-Years
-28%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Medmix Ltd
SIX:MEDX
Accrued Liabilities
CHf30.9m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Medacta Group SA
Glance View

Market Cap
2.1B CHF
Industry
Health Care

Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients. Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.

MOVE Intrinsic Value
125.23 CHF
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Medacta Group SA's Accrued Liabilities?
Accrued Liabilities
52.7m EUR

Based on the financial report for Dec 31, 2023, Medacta Group SA's Accrued Liabilities amounts to 52.7m EUR.

What is Medacta Group SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
5%

Over the last year, the Accrued Liabilities growth was 15%. The average annual Accrued Liabilities growth rates for Medacta Group SA have been 3% over the past three years , 5% over the past five years .

Back to Top